Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 4/20 | 0.72 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.72 |
| ▸ | LTB4R2 | Q9NPC1 | 3/20 | 0.72 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.69 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.69 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | GAA | P10253 | 1/20 | 0.69 |
| ▸ | EDNRA | P25101 | 1/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
| ▸ | HTR2B | P41595 | 1/20 | 0.69 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.69 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.69 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1317014 | 0.86 | ACHE (0.71) | ACHEAGTR1LTB4R2ABCC3ABCC4 | |
| SCHEMBL809907 | 0.85 | ACHE (0.63) | ACHEAGTR1LTB4R2ABCC3ABCC4 | |
| SCHEMBL812699 | 0.85 | ACHE (0.63) | ACHEAGTR1LTB4R2ABCC3ABCC4 | |
| SCHEMBL812700 | 0.85 | ACHE (0.63) | ACHEAGTR1LTB4R2ABCC3ABCC4 | |
| SCHEMBL24360482 | 0.85 | ACHE (0.72) | ACHEAGTR1LTB4R2ABCC3ABCC4 | |
| SCHEMBL1316335 | 0.84 | ACHE (1.00) | ACHEAGTR1LTB4R2ABCC3ABCC4 | |
| SCHEMBL29598156 | 0.84 | ACHE (1.00) | ACHEAGTR1LTB4R2ABCC3ABCC4 | |
| SCHEMBL684147 | 0.84 | AGTR1 (1.00) | ACHEAGTR1LTB4R2 | |
| SCHEMBL26688979 | 0.83 | ACHE (0.78) | ACHEAGTR1LTB4R2ABCC3ABCC4 | |
| SCHEMBL10027905 | 0.83 | AGTR1 (0.84) | ACHEAGTR1LTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968727-B2 | Synthesis of 4-bromomethyl-2′-formylbiphenyl and 4-bromomethyl-2′-hydroxymethylbiphenyl and its use in preparation of angiotensin II antagonists | LEK PHARMACEUTICALS, D.D. (SI) | 2011-06-28 | — | — | US | disclosed |
| US-7968727-B2 | Synthesis of 4-bromomethyl-2′-formylbiphenyl and 4-bromomethyl-2′-hydroxymethylbiphenyl and its use in preparation of angiotensin II antagonists | LEK PHARMACEUTICALS, D.D. (SI) | 2011-06-28 | — | — | US | disclosed |
| US-7968727-B2 | Synthesis of 4-bromomethyl-2′-formylbiphenyl and 4-bromomethyl-2′-hydroxymethylbiphenyl and its use in preparation of angiotensin II antagonists | LEK PHARMACEUTICALS, D.D. (SI) | 2011-06-28 | — | — | US | disclosed |
| US-20090318521-A1 | Synthesis of 4-Bromomethyl-2'-Formylbiphenyl and 4-Bromomethyl-2'-Hydroxymethylbiphenyl and Its Use in Preparation of Giotensin II Antagonists | LEK PHARMACEUTICALS D.D. (SI) | 2009-12-24 | — | — | US | disclosed |
| US-20090318521-A1 | Synthesis of 4-Bromomethyl-2'-Formylbiphenyl and 4-Bromomethyl-2'-Hydroxymethylbiphenyl and Its Use in Preparation of Giotensin II Antagonists | LEK PHARMACEUTICALS D.D. (SI) | 2009-12-24 | — | — | US | disclosed |
| US-20090318521-A1 | Synthesis of 4-Bromomethyl-2'-Formylbiphenyl and 4-Bromomethyl-2'-Hydroxymethylbiphenyl and Its Use in Preparation of Giotensin II Antagonists | LEK PHARMACEUTICALS D.D. (SI) | 2009-12-24 | — | — | US | disclosed |
| EP-1871764-A1 | A SYNTHESIS OF 4-BROMOMETHYL-2'-FORMYLBIPHENYL AND 4-BROMOMETHYL-2'- HYDROXYMETHYLBIPHENYL AND ITS USE IN PREPARATION OF ANGIOTENSIN II ANTAGONISTS | LEK Pharmaceuticals D.D. (SI) | 2008-01-02 | — | — | EP | disclosed |
| WO-2006103068-A1 | A SYNTHESIS OF 4-BROMOMETHYL-2'-FORMYLBIPHENYL AND 4-BROMOMETHYL-2'- HYDROXYMETHYLBIPHENYL AND ITS USE IN PREPARATION OF ANGIOTENSIN II ANTAGONISTS | LEK PHARMACEUTICALS D.D. (SI) | 2006-10-05 | — | — | WO | disclosed |
| WO-2006103068-A1 | A SYNTHESIS OF 4-BROMOMETHYL-2'-FORMYLBIPHENYL AND 4-BROMOMETHYL-2'- HYDROXYMETHYLBIPHENYL AND ITS USE IN PREPARATION OF ANGIOTENSIN II ANTAGONISTS | LEK PHARMACEUTICALS D.D. (SI) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318521-A1 | Synthesis of 4-Bromomethyl-2'-Formylbiphenyl and 4-Bromomethyl-2'-Hydroxymethylbiphenyl and Its Use in Preparation of Giotensin II Antagonists | GRK4, GRK2, GRK5 | ACHE 2178/4885AGTR1 43/4885LTB4R2 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.